文献速递淋巴瘤

基线18FDG-PET/CT扫描高代谢异质性是初诊弥漫大B细胞淋巴瘤的不良预后因素

High metabolic heterogeneity on baseline 18FDG-PET/CT scan as a poor prognostic factor for newly diagnosed diffuse large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2020-01-01

本研究探讨基线18F-氟脱氧葡萄糖(18FDG)PET/CT所测代谢异质性(MH)在初诊弥漫大B细胞淋巴瘤(DLBCL)中的预后价值。训练队列86例接受环磷酰胺、多柔比星、长春新碱、泼尼松类化疗的患者经受试者工作特征分析分为低MH组与高MH组,5年总生存率低MH组89.5% vs 高MH组61.2%(P = .0122),5年无事件生存率低MH组73.1% vs 高MH组51.1%(P = .0327)。多因素Cox回归分析显示MH是总生存的独立预测因素,高MH的不良预后影响在64例独立验证队列中得到证实。

要点

  • 训练队列中低MH组5年总生存率89.5%,高MH组61.2%(P = .0122)。
  • 训练队列中低MH组5年无事件生存率73.1%,高MH组51.1%(P = .0327)。
  • 多因素Cox回归分析显示MH是总生存的独立预测因素。

核心结论

  • 基线18FDG-PET/CT扫描所测MH可预测初诊DLBCL患者的治疗结局。

研究设计与样本

  • 研究纳入初诊DLBCL患者,训练队列86例接受环磷酰胺、多柔比星、长春新碱、泼尼松类化疗,经受试者工作特征分析分为低MH组和高MH组;另设64例患者的独立验证队列。

主要发现

  • MH与相应病灶的代谢肿瘤体积不相关,提示MH独立于肿瘤负荷。
  • 训练队列5年总生存率低MH组89.5% vs 高MH组61.2%(P = .0122)。
  • 训练队列5年无事件生存率低MH组73.1% vs 高MH组51.1%(P = .0327)。
  • 多因素Cox回归分析显示MH是总生存的独立预测因素。
  • 高MH的不良预后影响在64例独立验证队列中得到证实。

关键数值与推荐

  • 训练队列以受试者工作特征分析确定低MH组与高MH组的划分。
  • 训练队列5年总生存率低MH组89.5% vs 高MH组61.2%(P = .0122)。
  • 训练队列5年无事件生存率低MH组73.1% vs 高MH组51.1%(P = .0327)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Metabolic heterogeneity (MH) can be measured using 18F-fluorodeoxyglucose (18FDG) positron emission tomography/computed tomography (PET/CT), and it indicates an inhomogeneous tumor microenvironment. High MH has been shown to predict a worse prognosis for primary mediastinal B-cell lymphoma, whereas its prognostic value in diffuse large B-cell lymphoma (DLBCL) remains to be determined. In the current study, we investigated the prognostic values of MH evaluated in newly diagnosed DLBCL. In the training cohort, 86 patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone-like chemotherapies were divided into low-MH and high-MH groups using receiver operating characteristic analysis. MH was not correlated with metabolic tumor volume of the corresponding lesion, indicating that MH was independent of tumor burden. At 5 years, overall survivals were 89.5% vs 61.2% (P = .0122) and event-free survivals were 73.1% vs 51.1% (P = .0327) in the low- and high-MH groups, respectively. A multivariate Cox-regression analysis showed that MH was an independent predictive factor for overall survival. The adverse prognostic impacts of high MH were confirmed in an independent validation cohort with 64 patients. In conclusion, MH on baseline 18FDG-PET/CT scan predicts treatment outcomes for patients with newly diagnosed DLBCL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Senjo H, Hirata K, Izumiyama K, et al. High metabolic heterogeneity on baseline 18FDG-PET/CT scan as a poor prognostic factor for newly diagnosed diffuse large B-cell lymphoma. Blood Adv. 2020. PMID: 32453838. doi:10.1182/bloodadvances.2020001816

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。